HUMA · CIK 0001818382
What Humacyte, Inc. told the SEC could break it.
Humacyte is concentrated on a single product made at a single site. Its only approved product, Symvess, generated just $1.4 million in product revenue in fiscal 2025 (the rest of its revenue is grant- and contract-derived), and its corporate headquarters, manufacturing and R&D all sit in one roughly 83,000-square-foot leased facility in Durham, North Carolina, so a disruption there would hit every part of the business. Its prospects also turn on FDA decisions — the agency applied its own imputation methodology to V005 trial data in the Symvess package insert, materially changing the reported efficacy endpoints. Against continuing operating losses, it carries a high-cost Term Loan Facility (interest the greater of 11.5% or Prime plus 4.5%) secured by substantially all of its assets, where a default could allow acceleration against that collateral.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Geographic concentration
- Single facility — Durham, North Carolinamedium
Corporate HQ, manufacturing, and R&D are concentrated in a single ~83,000-sq-ft leased facility in Durham, NC, so a disruption there would impact all operations.
“Our corporate headquarters, manufacturing, and research and development facilities are located in Durham, North Carolina where we lease approximately 83,000 square feet of space.”
SEC filing →As of 2026
Other disclosures
- Single approved product (Symvess)medium
Revenue is concentrated in a single approved product, Symvess, which generated only $1.4 million in product revenue in FY2025; all other revenue is grant/contract-derived.
“During the fiscal year of 2025, we have generated $1.4 million in product revenue from the sale of Symvess.”
SEC filing →As of 2026
Regulatory & policy
- FDA approval / labeling of Symvessmedium
Dependent on FDA regulatory decisions; the FDA applied its own imputation methodology to V005 trial data in the Symvess package insert, materially changing reported efficacy endpoints.
“In the package insert for Symvess , the FDA applied a different imputing methodology for V005 Symvess patients who did not have a day 30 assessment.”
SEC filing →As of 2026
Liquidity & debt
- Term Loan Facility secured by substantially all assets (11.5% interest)low
High-cost Term Loan Facility (interest the greater of 11.5% or WSJ Prime + 4.5%) with liquidity covenants, secured by substantially all assets, against continuing operating losses; default permits acceleration against collateral.
“The Loan Agreement contains customary affirmative and negative covenants, certain liquidity requirements and customary events of default, and is secured by substantially all of our assets.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its suppliers
Confluent Medical Technologies, Inc.
“SeraCare, which was subsequently acquired by LGC Clinical Diagnostics, Inc. (“SeraCare”), is the current single source supplier of human plasma used in our manufacturing process and Confluent Medical Technologies, Inc. (“Confluent”) is the current single source supplier of the polymer mesh we use.”
Cited →LGC Clinical Diagnostics, Inc. (SeraCare)
“SeraCare, which was subsequently acquired by LGC Clinical Diagnostics, Inc. (“SeraCare”), is the current single source supplier of human plasma used in our manufacturing process and Confluent Medical Technologies, Inc. (“Confluent”) is the current single source supplier of the polymer mesh we use.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch